Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis.
Differentiating patients with allergic bronchopulmonary aspergillosis (ABPA) from patients with asthma who have immediate skin reactivity to Aspergillus fumigatus may be difficult when the characteristic clinical and laboratory findings of ABPA are absent. This article describes the response of ABPA patients to corticosteroid therapy. After treatment of the acute stage of the disease with corticosteroid therapy, all ABPA patients had greater than or equal to 35% reduction of the total serum IgE within 2 mo. In 30 exacerbations of ABPA in 15 patients, there was greater than or equal to 35% reduction total serum IgE, in 24 exacerbations within 2 mo. Of the six exacerbations with less than 35% reduction of total serum IgE, noncompliance to medical therapy was clearly documented in three exacerbations. In one exacerbation with a slowly resolving pulmonary infiltrate, 6 mo of corticosteroid therapy was required before the total IgE decreased 35%. The total serum IgE and its response to corticosteroid therapy is a sensitive marker in ABPA and can be considered an important aid in management of ABPA. Failure to achieve greater than 35% reduction of total serum IgE by 2 mo with the administration of corticosteroid therapy in patients highly suspected of ABPA should make one either question the diagnosis of ABPA or consider noncompliance of the patient to medical management with corticosteroids.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000908:Antibodies, Fungal / Q000032:analysis; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy / Q000276:immunology*; D001231:Aspergillus flavus / Q000276:immunology; D002648:Child; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use
D000908:Antibodies, Fungal; D007073:Immunoglobulin E; D011241:Prednisone